Obesity Clinical Trials

274 studies are recruiting for obesity in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. Advancing Biopsychosocial Care Training Initiative

   This project will compare two training approaches for US Preventive Services Task Force recommended obesity care in Federally Qualified Health Centers (FQHC) across four aims. Aim 1 compares patient-level effectiveness [i.e., patient relative weight change and the proportion of patients who achieve…

   Stage

   Not phased

   Ages

   5 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT07049861 on ClinicalTrials.gov

2. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

   Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-1 Research Site, Clearwater, Florida

   Locations

   71 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654361 on ClinicalTrials.gov

3. Cannabis for Obesity Trial

   The goal of this study is to determine the initial efficacy of once daily oral cannabis for weight loss in obese individuals.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   University of Kentucky, Lexington, Kentucky

   Run by

   Joshua A. Lile, Ph.D.

   See if you can join NCT06137365 on ClinicalTrials.gov

4. A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

   This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   CenExel Act- Anaheim Clinical Trials /ID# 283200, Anaheim, California

   Locations

   2 in total

   Run by

   AbbVie

   See if you can join NCT07291232 on ClinicalTrials.gov

5. Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

   The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abno…

   Stage

   Not phased

   Ages

   18 to 70

   Site

   University of Missouri School of Medicine, Columbia, Missouri

   Run by

   Bettina Mittendorfer

   See if you can join NCT06335771 on ClinicalTrials.gov

6. Motivating Increases in Physical Activity for Prevention of Weight Regain After Metabolic Bariatric Surgery

   The goal of this clinical trial is to learn if a psychological intervention can increase regular physical activity to help prevent weight regain after metabolic bariatric surgery in adults. The main questions it aims to answer are: 1. Does the psychological intervention increase physical activity? …

   Stage

   Not phased

   Ages

   18 to 64

   Site

   Hartford HealthCare, Hartford, Connecticut

   Run by

   Hartford Hospital

   See if you can join NCT06484621 on ClinicalTrials.gov

7. Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)

   The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abno…

   Stage

   Not phased

   Ages

   18 to 70

   Site

   University of Missouri School of Medicine, Columbia, Missouri

   Run by

   Bettina Mittendorfer

   See if you can join NCT06571474 on ClinicalTrials.gov

8. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

   The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona

   Locations

   40 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07589608 on ClinicalTrials.gov

9. Mechanistic Study of Inspiratory Training in Childhood Asthma (MICA)

   This is single-center cross-sectional mechanistic study in lean and obese children with moderate-severe asthma, followed by a randomized, SHAM-controlled trial of Inspiratory Training (IT). The primary outcome is to describe the contributions of inspiratory muscle dysfunction (IMD) and Small Airway…

   Stage

   Not phased

   Ages

   6 to 17

   Site

   Duke Health Center Creekstone, Durham, North Carolina

   Locations

   2 in total

   Run by

   Duke University

   See if you can join NCT05945355 on ClinicalTrials.gov

10. Upper Body Subcutaneous Exosome Release in Response to a Meal in Obesity

    The purpose of this study is to understand the specific outflow and difference between normal weight and volunteers with obesity of upper body subcutaneous adipose tissue in response to a mixed meal challenge by site specific cannulation of the superior epigastric vein. We will characterize the exo…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT07031297 on ClinicalTrials.gov

11. Routine Validation and Reproducibility Testing of Laboratory Measures and Research Techniques Used for Metabolism Research (VAL)

    The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility, which is necessary to perform high quality research on chronic diseases (obesity, pre-diabetes and type-2 diabetes, dyslip…

    Stage

    Not phased

    Ages

    18 to 75

    Site

    University of Missouri School of Medicine, Columbia, Missouri

    Run by

    Bettina Mittendorfer

    See if you can join NCT06286761 on ClinicalTrials.gov

12. Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

    More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these ag…

    Stage

    Phase 2

    Ages

    18 to 30

    Site

    Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT06411210 on ClinicalTrials.gov

13. Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

    This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    Valley Clinical Trials, Northridge, California

    Locations

    61 in total

    Run by

    Amgen

    See if you can join NCT07225686 on ClinicalTrials.gov

14. Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change

    Background: In a previous study, participants were lived at the NIH and randomly received either a low-fat or a low-carbohydrate diet for 2 weeks and then switched to the other diet for 2 more weeks. Participants who received the low-carbohydrate diet first lost more body fat at the end of the stud…

    Stage

    Not phased

    Ages

    18 to 50

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    See if you can join NCT06325722 on ClinicalTrials.gov

15. Fibrosis Lessens After Metabolic Surgery

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease aff…

    Stage

    Phase 4

    Ages

    18 to 75

    Site

    Cleveland Clinic, Cleveland, Ohio

    Locations

    22 in total

    Run by

    The Cleveland Clinic

    See if you can join NCT06374875 on ClinicalTrials.gov

16. A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

    This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001…

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    ICON Early Phase Services, LLC, Lenexa, Kansas

    Run by

    Novo Nordisk A/S

    See if you can join NCT07437079 on ClinicalTrials.gov

17. Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

    The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.

    Stage

    EARLY_Phase 1

    Ages

    18 to 45

    Site

    University of Missouri, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT05219799 on ClinicalTrials.gov

18. Pharmacogenetics of Response to GLP1R Agonists

    Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and…

    Stage

    Phase 1

    Ages

    18 to 89

    Site

    Amish Research Clinic, Lancaster, Pennsylvania

    Run by

    University of Maryland, Baltimore

    See if you can join NCT05071898 on ClinicalTrials.gov

19. Sit Less, Interact and Move More (SLIMM) 2 Study

    * Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown t…

    Stage

    Phase 2

    Ages

    20 and older

    Site

    Stanford University, Stanford, California

    Locations

    2 in total

    Run by

    Srinvasan Beddhu

    See if you can join NCT05173714 on ClinicalTrials.gov

20. Mechanisms Underlying Individual Variations of Taste and Smell in Obesity

    Background: Changes to the sense of taste or smell can change eating behavior. This may contribute to obesity. Researchers want to see how taste and smell perceptions that affect food choices may differ between people with obesity and without obesity. Objective: To understand the role that senses o…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    See if you can join NCT04714892 on ClinicalTrials.gov

21. Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

    Dr. Nanette Santoro proposes to test the specific question that obesity results in abnormal estradiol response at the level of the pituitary and hypothalamus. This will be shown in diminished pituitary sensitivity to gonadorelin releasing hormone with a reduced estradiol induced luteinizing hormone…

    Stage

    Phase 2

    Ages

    18 to 38

    Site

    University of Colorado School of Medicine, Aurora, Colorado

    Locations

    2 in total

    Run by

    University of Colorado, Denver

    See if you can join NCT06686537 on ClinicalTrials.gov

22. Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

    The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Altasciences Clinical LA, Inc., Cypress, California

    Run by

    Novo Nordisk A/S

    See if you can join NCT07225816 on ClinicalTrials.gov

23. Small Extracellular Vesicles and Insulin Action

    The goals of this research study are to: 1) understand why some people with obesity are protected from developing conditions such as type 2 diabetes and cardiovascular disease while others are more likely to develop obesity-related conditions; 2) assess the effect of small extracellular vesicles (s…

    Stage

    Not phased

    Ages

    25 to 55

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05933707 on ClinicalTrials.gov

24. Evaluation of a Novel Technology to Support Tailored Health Behavior Counseling in Rural Primary Care Clinics

    This project will conduct a pilot hybrid study that examines the implementation (Aims 1 \& 2) and preliminary effectiveness (Aim 3) of PREVENT, a digital health intervention, among patients with overweight/obesity (N=100) using a clinic-randomized design. The central hypothesis of the study is that…

    Stage

    Not phased

    Ages

    18 to 64

    Site

    Washington University in St. Louis, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06397729 on ClinicalTrials.gov

25. Low Oxygen Exposure and Weight Status

    The objective of the proposed double-blind, parallel-arm, randomized clinical trial is to evaluate changes in body weight and composition, assess determinants of energy balance (intake and expenditure), and measure modulators of energy balance, following 8 wk of calorie restriction (-500 kcal/d) in…

    Stage

    Not phased

    Ages

    22 to 65

    Site

    Pennington Biomedical Research Center, Baton Rouge, Louisiana

    Run by

    Pennington Biomedical Research Center

    See if you can join NCT05289310 on ClinicalTrials.gov